Tumor cells' response to chemotherapy is driven by randomness, shows study

byGarvan Institute of Medical ResearchNeuroblastoma cells (cyan) growing as a tumour and the surrounding collagen matrix (magenta). The cells are expressing a biosensor (JNK-KTR) that reads out

Updated on: January 23,2024

Tumor cells' response to chemotherapy is driven by randomness, shows study

byGarvan Institute of Medical ResearchNeuroblastoma cells (cyan) growing as a tumour and the surrounding collagen matrix (magenta). The cells are expressing a biosensor (JNK-KTR) that reads out

Updated on:January 23,2024

Researchers pinpoint tumor-related protein, slow progression of cancers

by University of Nebraska-LincolnThe University of Nebraska-Lincoln's Paul Black (left) and Concetta DiRusso have co-authored a new study that could improve the treatment of malignant tumors.

Updated on: June 11,2024

Researchers pinpoint tumor-related protein, slow progression of cancers

by University of Nebraska-LincolnThe University of Nebraska-Lincoln's Paul Black (left) and Concetta DiRusso have co-authored a new study that could improve the treatment of malignant tumors.

Updated on:June 11,2024

Interdisciplinary research team uses AI to quickly discover personalized cancer cures

byLouisiana State UniversityCancerOmicsNet is a graph-based AI model. The LSU research team ran it on 2,300 drugs against 359 cancer cell lines—more than 800,000 combinations. CancerOmicsNet pre

Updated on: December 28,2023

Interdisciplinary research team uses AI to quickly discover personalized cancer cures

byLouisiana State UniversityCancerOmicsNet is a graph-based AI model. The LSU research team ran it on 2,300 drugs against 359 cancer cell lines—more than 800,000 combinations. CancerOmicsNet pre

Updated on:December 28,2023

Researchers compare tumor characteristics, survival outcome of different bile duct cancers

byBoston University School of MedicineCredit: CC0 Public DomainCholangiocarcinoma (CCA) or bile duct cancer, is a rare, aggressive liver cancer with a poor prognosis, which occurs mostly in peop

Updated on: September 30,2024

Researchers compare tumor characteristics, survival outcome of different bile duct cancers

byBoston University School of MedicineCredit: CC0 Public DomainCholangiocarcinoma (CCA) or bile duct cancer, is a rare, aggressive liver cancer with a poor prognosis, which occurs mostly in peop

Updated on:September 30,2024

Research provides insight into genetic link to potential treatment response among BRCA1/2 breast cancer patients

by Alex Gardner,Perelman School of Medicine at the University of PennsylvaniaCredit: CC0 Public DomainNew findings from researchers in the Perelman School of Medicine at the University of Pennsy

Updated on: June 01,2024

Research provides insight into genetic link to potential treatment response among BRCA1/2 breast cancer patients

by Alex Gardner,Perelman School of Medicine at the University of PennsylvaniaCredit: CC0 Public DomainNew findings from researchers in the Perelman School of Medicine at the University of Pennsy

Updated on:June 01,2024

Milestone rating system improved residency knowledge ratings bias

by Elana GotkineAdoption of the Milestone ratings system in 2014 was associated with improvement in internal medicine (IM) residency knowledge ratings bias in Black or Latino residents, who are underr

Updated on: May 26,2024

Milestone rating system improved residency knowledge ratings bias

by Elana GotkineAdoption of the Milestone ratings system in 2014 was associated with improvement in internal medicine (IM) residency knowledge ratings bias in Black or Latino residents, who are underr

Updated on:May 26,2024

A new combination therapy regimen shows promising results for prostate cancer

by Huntsman Cancer InstituteCredit: CC0 Public DomainTALAPRO-2, a study led by Neeraj Agarwal, MD, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progress

Updated on: January 28,2024

A new combination therapy regimen shows promising results for prostate cancer

by Huntsman Cancer InstituteCredit: CC0 Public DomainTALAPRO-2, a study led by Neeraj Agarwal, MD, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progress

Updated on:January 28,2024

Exploring how gene mutations in tumors impact radiation sensitivity

byNorthwestern UniversityHigh-content irradiation platform reproducibility for the duration of the profiling effort. The signal-to-noise ratio (SNR), in blue represents the in-plate ratio of rad

Updated on: January 07,2024

Exploring how gene mutations in tumors impact radiation sensitivity

byNorthwestern UniversityHigh-content irradiation platform reproducibility for the duration of the profiling effort. The signal-to-noise ratio (SNR), in blue represents the in-plate ratio of rad

Updated on:January 07,2024

Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung can

Updated on: September 27,2024

Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung can

Updated on:September 27,2024

Tackling resistance to HIF2 drugs with an RNA-based therapy

byUT Southwestern Medical CenterDownregulation of HIF2α by ARO-HIF2 in patient tumor biopsies. Credit: Dr. Payal KapurExpected to be diagnosed in 2% of men and 1% of women in the U.S., kidney ca

Updated on: December 28,2023

Tackling resistance to HIF2 drugs with an RNA-based therapy

byUT Southwestern Medical CenterDownregulation of HIF2α by ARO-HIF2 in patient tumor biopsies. Credit: Dr. Payal KapurExpected to be diagnosed in 2% of men and 1% of women in the U.S., kidney ca

Updated on:December 28,2023

Is the pap smear on the way out?

by Steven Reinberg, Healthday Reporter(HealthDay)—The Pap test, used for over 50 years to spot the early signs of cervical cancer, may soon become a thing of the past, new research suggests.Its replac

Updated on: April 01,2024

Is the pap smear on the way out?

by Steven Reinberg, Healthday Reporter(HealthDay)—The Pap test, used for over 50 years to spot the early signs of cervical cancer, may soon become a thing of the past, new research suggests.Its replac

Updated on:April 01,2024

Researchers describe a new resistance mechanism

by IDIBELL-Bellvitge Biomedical Research InstituteDue to the treatment with the antibody against Semaphorin 4D (anti-Sema4D), changes occur in the tumor vasculature as well as a decrease in tumor

Updated on: June 08,2024

Researchers describe a new resistance mechanism

by IDIBELL-Bellvitge Biomedical Research InstituteDue to the treatment with the antibody against Semaphorin 4D (anti-Sema4D), changes occur in the tumor vasculature as well as a decrease in tumor

Updated on:June 08,2024